Pharmacoeconomics

Papers
(The H4-Index of Pharmacoeconomics is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”172
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling149
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children85
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy79
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment69
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?63
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis59
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned49
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment49
Bayesian Meta-Analysis: A Practical Introduction46
Advancing Methods to Measure and Reward Healthcare Innovation46
Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer46
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based 45
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review42
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA42
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review40
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States40
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies39
The Economic Burden of Inflammatory Arthritis: A Systematic Review38
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling37
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy35
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation34
Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects34
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions33
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review32
A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons31
Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey31
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition30
The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review29
0.23013210296631